Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to predict dangerous clot complications early

NCT ID NCT07491094

Knowledge-focused Sponsor: Sahlgrenska University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

This study follows 400 adults diagnosed with pulmonary embolism (a blood clot in the lungs) at a Swedish hospital. Researchers will repeatedly check heart tests and blood markers during the first 48 hours to see if early changes can better predict who will worsen. The goal is to improve understanding and create a long-term follow-up system, not to test a new drug or treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to predict which patients with pulmonary embolism are at risk of getting worse, helping doctors make faster, more informed decisions.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve health. The findings may not apply to all hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jan 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with pulmonary embolism during routine clinical care at Sahlgrenska University Hospital in Gothenburg. Patients are identified through hospital services responsible for the diagnosis and management of pulmonary embolism within the regional healthcare system of Region Västra Götaland (Sweden).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients (≥ 18 years old) who is diagnosed with, or followed as out-patients for, PE at Sahlgrenska University Hospital 2. Written informed consent Exclusion Criteria from Cohort A: 1. Low risk, intermediate-low risk or high risk PE\* 2. \>48 hours since PE diagnosis 3. Expected inability to comply with the protocol (e.g. dementia) Exclusion Criterium from Cohort B: 1\. Not geographically belonging to Sahlgrenska University Hospital \*If biomarkers (and/or echocardiography) are not available in hemodynamically stable patients, RV/LV-ratio \>1 will be considered as preliminary intermediate-high risk. If biomarkers later fall out negative, the patient will be considered as intermediate-low risk and will be moved to Cohort B

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary embolism (diagnosis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute cor pulmonale Clinical Deterioration Death disease pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary embolism (diagnosis) Pulmonary embolism (PE) Pulmonary embolism acute Pulmonary embolism with acute cor pulmonale Pulmonary embolism with right ventricle enlargement

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sahlgrenska University Hospital/Mölndal

    NOT_YET_RECRUITING

    Gothenburg, Region Västra Götaland, Sweden

  • Sahlgrenska University Hospital/Sahlgrenska

    RECRUITING

    Gothenburg, Region Västra Götaland, Sweden

  • Sahlgrenska University Hospital/Östra

    NOT_YET_RECRUITING

    Gothenburg, Region Västra Götaland, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.